Overview

Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors

Status:
Completed

Trial end date:
2016-01-25

Target enrollment:

Participant gender:

Summary

The primary purpose of the phase Ib is to estimate the MTD/RPD2 and of the phase II is to assess the anti-tumor activity of MEK162 in combination with panitumumab.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Array BioPharma
Pfizer

Treatments:

Antibodies, Monoclonal
Cetuximab
Panitumumab